메뉴 건너뛰기




Volumn 23, Issue 3, 2009, Pages 137-153

Progress on the induction of neutralizing antibodies against HIV type 1 (HIV-1)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; DNA VACCINE; FREUND ADJUVANT; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 140; GLYCOPROTEIN GP 160; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IDIOTYPIC ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN; VIRUS VACCINE;

EID: 68649086251     PISSN: 11738804     EISSN: 1179190X     Source Type: Journal    
DOI: 10.2165/00063030-200923030-00001     Document Type: Review
Times cited : (10)

References (128)
  • 1
    • 34547631086 scopus 로고    scopus 로고
    • online, Available from URL:, Accessed 2009 Apr 29
    • UNAIDS/WHO. Global AIDS epidemic continues to grow 2006 [online]. Available from URL: http://www.who.int/hiv/mediacentre/news62/en/index. html [Accessed 2009 Apr 29]
    • (2006) Global AIDS epidemic continues to grow
  • 2
    • 13944254982 scopus 로고    scopus 로고
    • Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection
    • Mar 1;
    • Flynn NM, Forthal DN, Harro CD,et al. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005 Mar 1; 191 (5): 654-65
    • (2005) J Infect Dis , vol.191 , Issue.5 , pp. 654-665
    • Flynn, N.M.1    Forthal, D.N.2    Harro, C.D.3
  • 3
    • 33845433434 scopus 로고    scopus 로고
    • Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand
    • Dec 15;
    • Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006 Dec 15; 194 (12): 1661-71
    • (2006) J Infect Dis , vol.194 , Issue.12 , pp. 1661-1671
    • Pitisuttithum, P.1    Gilbert, P.2    Gurwith, M.3
  • 4
    • 56649105122 scopus 로고    scopus 로고
    • Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): A double-blind, randomised, placebo-controlled, test-of-concept trial
    • Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372: 1881-93
    • (2008) Lancet , vol.372 , pp. 1881-1893
    • Buchbinder, S.P.1    Mehrotra, D.V.2    Duerr, A.3
  • 5
    • 0028041344 scopus 로고
    • Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection
    • Sep;
    • Borrow P, Lewicki H, Hahn BH, et al. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994 Sep; 68 (9): 6103-10
    • (1994) J Virol , vol.68 , Issue.9 , pp. 6103-6110
    • Borrow, P.1    Lewicki, H.2    Hahn, B.H.3
  • 6
    • 0028337166 scopus 로고
    • Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome
    • Jul;
    • Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994 Jul; 68 (7): 4650-5
    • (1994) J Virol , vol.68 , Issue.7 , pp. 4650-4655
    • Koup, R.A.1    Safrit, J.T.2    Cao, Y.3
  • 7
    • 0033524838 scopus 로고    scopus 로고
    • Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes
    • Feb 5;
    • Schmitz JE, Kuroda MJ, Santra S, et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999 Feb 5; 283 (5403): 857-60
    • (1999) Science , vol.283 , Issue.5403 , pp. 857-860
    • Schmitz, J.E.1    Kuroda, M.J.2    Santra, S.3
  • 8
    • 0032512004 scopus 로고    scopus 로고
    • HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons
    • Nov 12;
    • Bernard NF, Pederson K, Chung F, et al. HIV-specific cytotoxic T-lymphocyte activity in immunologically normal HIV-infected persons. AIDS 1998 Nov 12; 12 (16): 2125-39
    • (1998) AIDS , vol.12 , Issue.16 , pp. 2125-2139
    • Bernard, N.F.1    Pederson, K.2    Chung, F.3
  • 9
    • 0031664158 scopus 로고    scopus 로고
    • Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: A predominant gag-specific response is associated with non-progressive infection
    • Oct;
    • Pontesilli O, Klein MR, Kerkhof-Garde SR, et al. Longitudinal analysis of human immunodeficiency virus type 1-specific cytotoxic T lymphocyte responses: a predominant gag-specific response is associated with non-progressive infection. J Infect Dis 1998 Oct; 178 (4): 1008-18
    • (1998) J Infect Dis , vol.178 , Issue.4 , pp. 1008-1018
    • Pontesilli, O.1    Klein, M.R.2    Kerkhof-Garde, S.R.3
  • 10
    • 0035815437 scopus 로고    scopus 로고
    • Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine
    • Apr 6;
    • Amara RR, Villinger F, Altman JD, et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 2001 Apr 6; 292 (5514): 69-74
    • (2001) Science , vol.292 , Issue.5514 , pp. 69-74
    • Amara, R.R.1    Villinger, F.2    Altman, J.D.3
  • 11
    • 0037122719 scopus 로고    scopus 로고
    • Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity
    • Jan 17;
    • Shiver JW, FuTM, ChenL,etal. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 2002 Jan 17; 415 (6869): 331-5
    • (2002) Nature , vol.415 , Issue.6869 , pp. 331-335
    • Shiver, J.W.1    Fu, T.M.2    Chen, L.3
  • 12
    • 0033766645 scopus 로고    scopus 로고
    • Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augumented DNA vaccination
    • Oct 20;
    • Barouch DH, Santra S, Schmitz JE, et al. Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augumented DNA vaccination. Science 2000 Oct 20; 290: 486-92
    • (2000) Science , vol.290 , pp. 486-492
    • Barouch, D.H.1    Santra, S.2    Schmitz, J.E.3
  • 13
    • 29244455769 scopus 로고    scopus 로고
    • Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag
    • Casimiro D, Wang F, Schleif W, et al. Attenuation of simian immunodeficiency virus SIVmac239 infection by prophylactic immunization with dna and recombinant adenoviral vaccine vectors expressing Gag. J Virol 2005; 79 (24): 15547-55
    • (2005) J Virol , vol.79 , Issue.24 , pp. 15547-15555
    • Casimiro, D.1    Wang, F.2    Schleif, W.3
  • 14
    • 25144485385 scopus 로고    scopus 로고
    • Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesusmonkeys
    • Oct;
    • Liang X, Casimiro DR, Schleif WA, et al. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesusmonkeys. JVirol 2005 Oct;79(19): 12321-31
    • (2005) JVirol , vol.79 , Issue.19 , pp. 12321-12331
    • Liang, X.1    Casimiro, D.R.2    Schleif, W.A.3
  • 15
    • 35748968205 scopus 로고    scopus 로고
    • HIV vaccine failure prompts Merck to halt trial. Nature 2007 Sep 27; 449 (7161): 390
    • HIV vaccine failure prompts Merck to halt trial. Nature 2007 Sep 27; 449 (7161): 390
  • 16
    • 37549033167 scopus 로고    scopus 로고
    • One step forward, two steps back: Will there ever be an AIDS vaccine?
    • Dec 27;
    • Steinbrook R. One step forward, two steps back: will there ever be an AIDS vaccine? N Engl J Med 2007 Dec 27; 357 (26): 2653-5
    • (2007) N Engl J Med , vol.357 , Issue.26 , pp. 2653-2655
    • Steinbrook, R.1
  • 17
    • 38349151669 scopus 로고    scopus 로고
    • HIV-1 T-cell vaccines: Evaluating the next step
    • Feb;
    • Pantaleo G. HIV-1 T-cell vaccines: evaluating the next step. Lancet Infect Dis 2008 Feb; 8 (2): 82-3
    • (2008) Lancet Infect Dis , vol.8 , Issue.2 , pp. 82-83
    • Pantaleo, G.1
  • 18
    • 36248941489 scopus 로고    scopus 로고
    • HIV vaccine may raise risk
    • Nov 15;
    • Ledford H. HIV vaccine may raise risk. Nature 2007 Nov 15; 450 (7168): 325
    • (2007) Nature , vol.450 , Issue.7168 , pp. 325
    • Ledford, H.1
  • 19
    • 0035162494 scopus 로고    scopus 로고
    • Evolutionary and immunological implications of contemporary HIV-1 variation
    • Korber B, Gaschen B, Yusim K, et al. Evolutionary and immunological implications of contemporary HIV-1 variation. Br Med Bull 2001; 58: 19-42
    • (2001) Br Med Bull , vol.58 , pp. 19-42
    • Korber, B.1    Gaschen, B.2    Yusim, K.3
  • 20
    • 33646146379 scopus 로고    scopus 로고
    • GP120: Target for neutralizing HIV-1 antibodies
    • Pantophlet R, Burton DR. GP120: target for neutralizing HIV-1 antibodies. Annu Rev Immunol 2006; 24: 739-69
    • (2006) Annu Rev Immunol , vol.24 , pp. 739-769
    • Pantophlet, R.1    Burton, D.R.2
  • 21
    • 27244460793 scopus 로고    scopus 로고
    • Antibody vs HIV in a clash of evolutionary titans
    • Oct 18;
    • Burton DR, Stanfield RL, Wilson IA. Antibody vs HIV in a clash of evolutionary titans. Proc Natl Acad Sci U S A 2005 Oct 18; 102 (42): 14943-8
    • (2005) Proc Natl Acad Sci U S A , vol.102 , Issue.42 , pp. 14943-14948
    • Burton, D.R.1    Stanfield, R.L.2    Wilson, I.A.3
  • 22
    • 9544239346 scopus 로고    scopus 로고
    • The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate
    • Oct;
    • Conley AJ, Kessler II JA, Boots LJ, et al. The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate. J Virol 1996 Oct; 70 (10): 6751-8
    • (1996) J Virol , vol.70 , Issue.10 , pp. 6751-6758
    • Conley, A.J.1    Kessler II, J.A.2    Boots, L.J.3
  • 23
    • 0026557112 scopus 로고
    • Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody
    • Feb 20;
    • Emini EA, Schleif WA, Nunberg JH, et al. Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody. Nature 1992 Feb 20; 355 (6362): 728-30
    • (1992) Nature , vol.355 , Issue.6362 , pp. 728-730
    • Emini, E.A.1    Schleif, W.A.2    Nunberg, J.H.3
  • 24
    • 0036307928 scopus 로고    scopus 로고
    • Postnatal pre- and postexposure passive immunization strategies: Protection of neonatal macaques against oral simian-human immunodeficiency virus challenge
    • Jun;
    • Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal pre- and postexposure passive immunization strategies: protection of neonatal macaques against oral simian-human immunodeficiency virus challenge. J Med Primatol 2002 Jun; 31 (3): 109-19
    • (2002) J Med Primatol , vol.31 , Issue.3 , pp. 109-119
    • Hofmann-Lehmann, R.1    Vlasak, J.2    Rasmussen, R.A.3
  • 25
    • 0034904087 scopus 로고    scopus 로고
    • Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge
    • Aug;
    • Hofmann-Lehmann R, Vlasak J, Rasmussen RA, et al. Postnatal passive immunization of neonatal macaques with a triple combination of human monoclonal antibodies against oral simian-human immunodeficiency virus challenge. J Virol 2001 Aug; 75 (16): 7470-80
    • (2001) J Virol , vol.75 , Issue.16 , pp. 7470-7480
    • Hofmann-Lehmann, R.1    Vlasak, J.2    Rasmussen, R.A.3
  • 26
    • 0032947286 scopus 로고    scopus 로고
    • Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies
    • May;
    • Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999 May; 73 (5): 4009-18
    • (1999) J Virol , vol.73 , Issue.5 , pp. 4009-4018
    • Mascola, J.R.1    Lewis, M.G.2    Stiegler, G.3
  • 27
    • 0033951746 scopus 로고    scopus 로고
    • Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virusby passive infusion of neutralizing antibodies
    • Feb;
    • Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virusby passive infusion of neutralizing antibodies. Nat Med 2000 Feb;6 (2): 207-10
    • (2000) Nat Med , vol.6 , Issue.2 , pp. 207-210
    • Mascola, J.R.1    Stiegler, G.2    VanCott, T.C.3
  • 28
    • 0025331727 scopus 로고
    • Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160
    • Jun 14;
    • Berman PW, Gregory TJ, Riddle L, et al. Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160. Nature 1990 Jun 14; 345 (6276): 622-5
    • (1990) Nature , vol.345 , Issue.6276 , pp. 622-625
    • Berman, P.W.1    Gregory, T.J.2    Riddle, L.3
  • 29
    • 0028892847 scopus 로고
    • Resistance of chimpanzees immunized with recombinant gp120SF2to challenge byHIV-1SF2
    • Dec;
    • el-Amad Z, Murthy KK, Higgins K, et al. Resistance of chimpanzees immunized with recombinant gp120SF2to challenge byHIV-1SF2. AIDS 1995 Dec; 9 (12): 1313-22
    • (1995) AIDS , vol.9 , Issue.12 , pp. 1313-1322
    • el-Amad, Z.1    Murthy, K.K.2    Higgins, K.3
  • 30
    • 19144370387 scopus 로고    scopus 로고
    • Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1
    • Jan;
    • Berman PW, Murthy KK, Wrin T, et al. Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1. J Infect Dis 1996 Jan; 173 (1): 52-9
    • (1996) J Infect Dis , vol.173 , Issue.1 , pp. 52-59
    • Berman, P.W.1    Murthy, K.K.2    Wrin, T.3
  • 31
    • 0027178289 scopus 로고
    • Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine
    • Jul 10;
    • Schwartz DH, Gorse G, Clements ML, et al. Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected recipients of HIV-1IIIB rgp120 subunit vaccine. Lancet 1993 Jul 10; 342 (8863): 69-73
    • (1993) Lancet , vol.342 , Issue.8863 , pp. 69-73
    • Schwartz, D.H.1    Gorse, G.2    Clements, M.L.3
  • 32
    • 0027430975 scopus 로고
    • Safety and immunogenicity of afully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network
    • Dec;
    • Belshe RB, Clements ML, Dolin R, etal. Safety and immunogenicity of afully glycosylated recombinant gp160 human immunodeficiency virus type 1 vaccine in subjects at low risk of infection. National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group Network. J Infect Dis 1993 Dec; 168 (6): 1387-95
    • (1993) J Infect Dis , vol.168 , Issue.6 , pp. 1387-1395
    • Belshe, R.B.1    Clements, M.L.2    Dolin, R.3
  • 33
    • 0028024901 scopus 로고
    • Neutralizing antibodiestoHIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain ofHIV-1. NIAID AIDS Vaccine Clinical TrialsNetwork
    • Aug 10;
    • Belshe RB, Graham BS, Keefer MC,et al. Neutralizing antibodiestoHIV-1 in seronegative volunteers immunized with recombinant gp120 from the MN strain ofHIV-1. NIAID AIDS Vaccine Clinical TrialsNetwork. JAMA 1994 Aug 10; 272 (6): 475-80
    • (1994) JAMA , vol.272 , Issue.6 , pp. 475-480
    • Belshe, R.B.1    Graham, B.S.2    Keefer, M.C.3
  • 34
    • 0030586434 scopus 로고    scopus 로고
    • Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: Recombinant glycoprotein (rgp) 120: a randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group
    • Aug 15;
    • Graham BS, Keefer MC, McElrath MJ, et al. Safety and immunogenicity of a candidate HIV-1 vaccine in healthy adults: recombinant glycoprotein (rgp) 120: a randomized, double-blind trial. NIAID AIDS Vaccine Evaluation Group. Ann Intern Med 1996 Aug 15; 125 (4): 270-9
    • (1996) Ann Intern Med , vol.125 , Issue.4 , pp. 270-279
    • Graham, B.S.1    Keefer, M.C.2    McElrath, M.J.3
  • 35
    • 4444309788 scopus 로고    scopus 로고
    • Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
    • Sep 1;
    • Pitisuttithum P, Berman PW, Phonrat B, et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1. J Acquir Immune Defic Syndr 2004 Sep 1; 37 (1): 1160-5
    • (2004) J Acquir Immune Defic Syndr , vol.37 , Issue.1 , pp. 1160-1165
    • Pitisuttithum, P.1    Berman, P.W.2    Phonrat, B.3
  • 36
    • 0031763443 scopus 로고    scopus 로고
    • Advancing AIDSVAX to phase 3: Safety, immunogenicity, and plans for phase 3
    • Oct;
    • Francis DP, Gregory T, McElrath MJ, et al. Advancing AIDSVAX to phase 3: safety, immunogenicity, and plans for phase 3. AIDS Res Hum Retroviruses 1998 Oct; 14 Suppl. 3: S325-31
    • (1998) AIDS Res Hum Retroviruses , vol.14 , Issue.SUPPL. 3
    • Francis, D.P.1    Gregory, T.2    McElrath, M.J.3
  • 37
    • 13944250922 scopus 로고    scopus 로고
    • Correlation between im-munologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial
    • Mar 1;
    • Gilbert PB, Peterson ML, Follmann D, et al. Correlation between im-munologic responses to a recombinant glycoprotein 120 vaccine and incidence of HIV-1 infection in a phase 3 HIV-1 preventive vaccine trial. J Infect Dis 2005 Mar 1; 191 (5): 666-77
    • (2005) J Infect Dis , vol.191 , Issue.5 , pp. 666-677
    • Gilbert, P.B.1    Peterson, M.L.2    Follmann, D.3
  • 38
    • 19944427052 scopus 로고    scopus 로고
    • Gao F, Weaver EA, Lu Z, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 2005 Jan 2005; 79 (2): 1154-63
    • Gao F, Weaver EA, Lu Z, et al. Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group M consensus envelope glycoprotein. J Virol 2005 Jan 2005; 79 (2): 1154-63
  • 39
    • 33746689169 scopus 로고    scopus 로고
    • A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses
    • Sep 30;
    • Liao HX, Sutherland LL, Xia SM, et al. A group M consensus envelope glycoprotein induces antibodies that neutralize subsets of subtype B and C HIV-1 primary viruses. Virology 2006 Sep 30; 353 (2): 268-82
    • (2006) Virology , vol.353 , Issue.2 , pp. 268-282
    • Liao, H.X.1    Sutherland, L.L.2    Xia, S.M.3
  • 40
    • 33847266930 scopus 로고    scopus 로고
    • Antigenicity and immunogenicityofHIV-1 consensus subtype B envelope glycoproteins
    • Mar 30;
    • Kothe DL, Decker JM, LiY,et al. Antigenicity and immunogenicityofHIV-1 consensus subtype B envelope glycoproteins. Virology 2007 Mar 30; 360 (1): 218-34
    • (2007) Virology , vol.360 , Issue.1 , pp. 218-234
    • Kothe, D.L.1    Decker, J.M.2    LiY3
  • 41
    • 33747041588 scopus 로고    scopus 로고
    • Ancestral and consensus envelope im-munogens for HIV-1 subtype C
    • Sep 1;
    • Kothe DL, Li Y, Decker JM, et al. Ancestral and consensus envelope im-munogens for HIV-1 subtype C. Virology 2006 Sep 1; 352 (2): 438-49
    • (2006) Virology , vol.352 , Issue.2 , pp. 438-449
    • Kothe, D.L.1    Li, Y.2    Decker, J.M.3
  • 42
    • 23844468382 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope
    • Sep;
    • Doria-Rose NA, Learn GH, Rodrigo AG, et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope. J Virol 2005 Sep; 79 (17): 11214-24
    • (2005) J Virol , vol.79 , Issue.17 , pp. 11214-11224
    • Doria-Rose, N.A.1    Learn, G.H.2    Rodrigo, A.G.3
  • 43
    • 0031906852 scopus 로고    scopus 로고
    • Immunogenicity of DNA vaccines expressing human immunodeficiency virus type1envelope glycoprotein with and without deletions in the V1/2 and V3 regions
    • Lu S, Wyatt R, Richmond JF, et al. Immunogenicity of DNA vaccines expressing human immunodeficiency virus type1envelope glycoprotein with and without deletions in the V1/2 and V3 regions. AIDS Res Hum Retroviruses 1998; 14 (2): 151-5
    • (1998) AIDS Res Hum Retroviruses , vol.14 , Issue.2 , pp. 151-155
    • Lu, S.1    Wyatt, R.2    Richmond, J.F.3
  • 44
    • 33748650781 scopus 로고    scopus 로고
    • Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: Comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection
    • Sep;
    • Derby NR, Kraft Z, Kan E, et al. Antibody responses elicited in macaques immunized with human immunodeficiency virus type 1 (HIV-1) SF162-derived gp140 envelope immunogens: comparison with those elicited during homologous simian/human immunodeficiency virus SHIVSF162P4 and heterologous HIV-1 infection. J Virol 2006 Sep; 80 (17): 8745-62
    • (2006) J Virol , vol.80 , Issue.17 , pp. 8745-8762
    • Derby, N.R.1    Kraft, Z.2    Kan, E.3
  • 45
    • 0037225248 scopus 로고    scopus 로고
    • Immunogenicity and ability of variable loopdeleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies
    • Jan 5;
    • Kim YB, Han DP, Cao C, et al. Immunogenicity and ability of variable loopdeleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. Virology 2003 Jan 5; 305 (1): 124-37
    • (2003) Virology , vol.305 , Issue.1 , pp. 124-137
    • Kim, Y.B.1    Han, D.P.2    Cao, C.3
  • 46
    • 0035000679 scopus 로고    scopus 로고
    • The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region
    • Jun;
    • Barnett SW, Lu S, Srivastava I, et al. The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region. J Virol 2001 Jun; 75 (12): 5526-40
    • (2001) J Virol , vol.75 , Issue.12 , pp. 5526-5540
    • Barnett, S.W.1    Lu, S.2    Srivastava, I.3
  • 47
    • 27144524041 scopus 로고    scopus 로고
    • Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain
    • Nov;
    • Lian Y, Srivastava I, Gomez-Roman VR, et al. Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain. J Virol 2005 Nov; 79 (21): 13338-49
    • (2005) J Virol , vol.79 , Issue.21 , pp. 13338-13349
    • Lian, Y.1    Srivastava, I.2    Gomez-Roman, V.R.3
  • 48
    • 0141788494 scopus 로고    scopus 로고
    • Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate
    • Oct;
    • Srivastava IK, Stamatatos L, Kan E, et al. Purification, characterization, and immunogenicity of a soluble trimeric envelope protein containing a partial deletion of the V2 loop derived from SF162, an R5-tropic human immunodeficiency virus type 1 isolate. J Virol 2003 Oct; 77 (20): 11244-59
    • (2003) J Virol , vol.77 , Issue.20 , pp. 11244-11259
    • Srivastava, I.K.1    Stamatatos, L.2    Kan, E.3
  • 49
    • 25144477447 scopus 로고    scopus 로고
    • Comparing antigenicity and immunogenicity of engineered gp120
    • Oct;
    • Selvarajah S, Puffer B, Pantophlet R, et al. Comparing antigenicity and immunogenicity of engineered gp120. J Virol 2005 Oct; 79 (19): 12148-63
    • (2005) J Virol , vol.79 , Issue.19 , pp. 12148-12163
    • Selvarajah, S.1    Puffer, B.2    Pantophlet, R.3
  • 50
    • 39549097297 scopus 로고    scopus 로고
    • Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140
    • Feb;
    • Selvarajah S, Puffer BA, Lee FH, et al. Focused dampening of antibody response to the immunodominant variable loops by engineered soluble gp140. AIDS Res Hum Retroviruses 2008 Feb; 24 (2): 301-14
    • (2008) AIDS Res Hum Retroviruses , vol.24 , Issue.2 , pp. 301-314
    • Selvarajah, S.1    Puffer, B.A.2    Lee, F.H.3
  • 51
    • 0031749469 scopus 로고    scopus 로고
    • A role for carbohydrates in immune evasion in AIDS
    • Jun;
    • Reitter JN, Means RE, Desrosiers RC. A role for carbohydrates in immune evasion in AIDS. Nat Med 1998 Jun; 4 (6): 679-84
    • (1998) Nat Med , vol.4 , Issue.6 , pp. 679-684
    • Reitter, J.N.1    Means, R.E.2    Desrosiers, R.C.3
  • 52
    • 37849026069 scopus 로고    scopus 로고
    • Removal of a single N-linked glycan in human immunodeficiency virus type1 gp120 results in anenhanced ability to induce neutralizing antibody responses
    • Jan;
    • Li Y, Cleveland B, Klots I, et al. Removal of a single N-linked glycan in human immunodeficiency virus type1 gp120 results in anenhanced ability to induce neutralizing antibody responses. J Virol 2008 Jan; 82 (2): 638-51
    • (2008) J Virol , vol.82 , Issue.2 , pp. 638-651
    • Li, Y.1    Cleveland, B.2    Klots, I.3
  • 53
    • 0030016341 scopus 로고    scopus 로고
    • Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response
    • Jul;
    • Bolmstedt A, Sjolander S, Hansen JE, et al. Influence of N-linked glycans in V4-V5 region of human immunodeficiency virus type 1 glycoprotein gp160 on induction of a virus-neutralizing humoral response. J Acquir Immune Defic Syndr Hum Retrovirol 1996 Jul; 12 (3): 213-20
    • (1996) J Acquir Immune Defic Syndr Hum Retrovirol , vol.12 , Issue.3 , pp. 213-220
    • Bolmstedt, A.1    Sjolander, S.2    Hansen, J.E.3
  • 54
    • 0036229473 scopus 로고    scopus 로고
    • Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: Effects on protein function and the neutralizing antibody response
    • May;
    • Quinones-Kochs MI, Buonocore L, Rose JK. Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol 2002 May; 76 (9): 4199-211
    • (2002) J Virol , vol.76 , Issue.9 , pp. 4199-4211
    • Quinones-Kochs, M.I.1    Buonocore, L.2    Rose, J.K.3
  • 55
    • 0035168058 scopus 로고    scopus 로고
    • Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140
    • Jan;
    • Earl PL, Sugiura W, Montefiori DC, et al. Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140. J Virol 2001 Jan; 75 (2): 645-53
    • (2001) J Virol , vol.75 , Issue.2 , pp. 645-653
    • Earl, P.L.1    Sugiura, W.2    Montefiori, D.C.3
  • 56
    • 34547154404 scopus 로고    scopus 로고
    • Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization
    • Jun 12;
    • Zhang PF, Cham F, Dong M, et al. Extensively cross-reactive anti-HIV-1 neutralizing antibodies induced by gp140 immunization. Proc Natl Acad Sci U S A 2007 Jun 12; 104 (24): 10193-8
    • (2007) Proc Natl Acad Sci U S A , vol.104 , Issue.24 , pp. 10193-10198
    • Zhang, P.F.1    Cham, F.2    Dong, M.3
  • 57
    • 21644445378 scopus 로고    scopus 로고
    • Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
    • Jul;
    • Beddows S, Schulke N, Kirschner M, et al. Evaluating the immunogenicity of a disulfide-stabilized, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2005 Jul; 79 (14): 8812-27
    • (2005) J Virol , vol.79 , Issue.14 , pp. 8812-8827
    • Beddows, S.1    Schulke, N.2    Kirschner, M.3
  • 58
    • 0035155850 scopus 로고    scopus 로고
    • Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers
    • Feb;
    • Yang X, Wyatt R, Sodroski J. Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers. J Virol 2001 Feb; 75 (3): 1165-71
    • (2001) J Virol , vol.75 , Issue.3 , pp. 1165-1171
    • Yang, X.1    Wyatt, R.2    Sodroski, J.3
  • 59
    • 31144451337 scopus 로고    scopus 로고
    • Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants
    • Feb;
    • Li Y, Svehla K, Mathy NL, et al. Characterization of antibody responses elicited by human immunodeficiency virus type 1 primary isolate trimeric and monomeric envelope glycoproteins in selected adjuvants. J Virol 2006 Feb; 80 (3): 1414-26
    • (2006) J Virol , vol.80 , Issue.3 , pp. 1414-1426
    • Li, Y.1    Svehla, K.2    Mathy, N.L.3
  • 60
    • 34249827906 scopus 로고    scopus 로고
    • Characterization of human immunodeficiency virus type1monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: Antigenicity, biophysics, and immunogenicity
    • Jun;
    • Dey B, Pancera M, Svehla K, et al. Characterization of human immunodeficiency virus type1monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol 2007 Jun; 81 (11): 5579-93
    • (2007) J Virol , vol.81 , Issue.11 , pp. 5579-5593
    • Dey, B.1    Pancera, M.2    Svehla, K.3
  • 61
    • 0033575483 scopus 로고    scopus 로고
    • Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein
    • Liang X, Munshi S, Shendure J, et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. Vaccine 1999; 17: 2862-72
    • (1999) Vaccine , vol.17 , pp. 2862-2872
    • Liang, X.1    Munshi, S.2    Shendure, J.3
  • 62
    • 34247166722 scopus 로고    scopus 로고
    • Law M, Cardoso RM, Wilson IA, et al. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.JVirol 2007 Apr; 81(8): 4272-85
    • Law M, Cardoso RM, Wilson IA, et al. Antigenic and immunogenic study of membrane-proximal external region-grafted gp120 antigens by a DNA prime-protein boost immunization strategy.JVirol 2007 Apr; 81(8): 4272-85
  • 63
    • 23244467373 scopus 로고    scopus 로고
    • Recommendations for the design and use ofstandard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines
    • Aug;
    • Mascola JR, D'Souza P, GilbertP,et al. Recommendations for the design and use ofstandard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005 Aug; 79 (16): 10103-7
    • (2005) J Virol , vol.79 , Issue.16 , pp. 10103-10107
    • Mascola, J.R.1    D'Souza, P.2    GilbertP3
  • 64
    • 23244434512 scopus 로고    scopus 로고
    • Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies
    • Aug;
    • Li M, Gao F, Mascola JR, et al. Human immunodeficiency virus type 1 Env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005 Aug; 79 (16): 10108-25
    • (2005) J Virol , vol.79 , Issue.16 , pp. 10108-10125
    • Li, M.1    Gao, F.2    Mascola, J.R.3
  • 65
    • 0031666180 scopus 로고    scopus 로고
    • An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades
    • Oct;
    • Stamatatos L, Cheng-Mayer C. An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades. J Virol 1998 Oct; 72 (10): 7840-5
    • (1998) J Virol , vol.72 , Issue.10 , pp. 7840-7845
    • Stamatatos, L.1    Cheng-Mayer, C.2
  • 66
    • 2342644898 scopus 로고    scopus 로고
    • The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection
    • May;
    • Pinter A, Honnen WJ, He Y, et al. The V1/V2 domain of gp120 is a global regulator of the sensitivity of primary human immunodeficiency virus type 1 isolates to neutralization by antibodies commonly induced upon infection. J Virol 2004 May; 78 (10): 5205-15
    • (2004) J Virol , vol.78 , Issue.10 , pp. 5205-5215
    • Pinter, A.1    Honnen, W.J.2    He, Y.3
  • 67
    • 0141458878 scopus 로고    scopus 로고
    • Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities
    • Sep;
    • Johnson WE, Sanford H, Schwall L, et al. Assorted mutations in the envelope gene of simian immunodeficiency virus lead to loss of neutralization resistance against antibodies representing a broad spectrum of specificities. J Virol 2003 Sep; 77 (18): 9993-10003
    • (2003) J Virol , vol.77 , Issue.18 , pp. 9993-10003
    • Johnson, W.E.1    Sanford, H.2    Schwall, L.3
  • 68
    • 0030812563 scopus 로고    scopus 로고
    • Replication and neutralizationof human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein
    • Dec;
    • Cao J,Sullivan N, Desjardin E,et al. Replication and neutralizationof human immunodeficiency virus type 1 lacking the V1 and V2 variable loops of the gp120 envelope glycoprotein. J Virol 1997 Dec; 71 (12): 9808-12
    • (1997) J Virol , vol.71 , Issue.12 , pp. 9808-9812
    • Cao, J.1    Sullivan, N.2    Desjardin, E.3
  • 69
    • 0037321708 scopus 로고    scopus 로고
    • Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region
    • Feb;
    • Srivastava IK, VanDorsten K, Vojtech L, et al. Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region. J Virol 2003 Feb; 77 (4): 2310-20
    • (2003) J Virol , vol.77 , Issue.4 , pp. 2310-2320
    • Srivastava, I.K.1    VanDorsten, K.2    Vojtech, L.3
  • 70
    • 0028244285 scopus 로고
    • An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization
    • Mar;
    • Back NK, Smit L, De Jong JJ, et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. Virology 1994 Mar; 199 (2): 431-8
    • (1994) Virology , vol.199 , Issue.2 , pp. 431-438
    • Back, N.K.1    Smit, L.2    De Jong, J.J.3
  • 71
    • 9944225582 scopus 로고    scopus 로고
    • Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies
    • Jan 5;
    • Kang SM, Quan FS, Huang C, et al. Modified HIV envelope proteins with enhanced binding to neutralizing monoclonal antibodies. Virology 2005 Jan 5; 331 (1): 20-32
    • (2005) Virology , vol.331 , Issue.1 , pp. 20-32
    • Kang, S.M.1    Quan, F.S.2    Huang, C.3
  • 72
    • 1842562419 scopus 로고    scopus 로고
    • N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies
    • Apr;
    • McCaffrey RA, Saunders C, Hensel M, et al. N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 2004 Apr; 78 (7): 3279-95
    • (2004) J Virol , vol.78 , Issue.7 , pp. 3279-3295
    • McCaffrey, R.A.1    Saunders, C.2    Hensel, M.3
  • 73
    • 2942525411 scopus 로고    scopus 로고
    • HIV-1 acute infection Env glycomutants designed from 3D model: Effects on processing, antigenicity, and neutralization sensitivity
    • Jun 20;
    • Reynard F, FatmiA, Verrier B, et al. HIV-1 acute infection Env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity. Virology 2004 Jun 20; 324 (1): 90-102
    • (2004) Virology , vol.324 , Issue.1 , pp. 90-102
    • Reynard, F.1    Fatmi, A.2    Verrier, B.3
  • 74
    • 0041920924 scopus 로고    scopus 로고
    • Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition
    • Sep 1;
    • Koch M, Pancera M, Kwong PD, et al. Structure-based, targeted deglycosylation of HIV-1 gp120 and effects on neutralization sensitivity and antibody recognition. Virology 2003 Sep 1; 313 (2): 387-400
    • (2003) Virology , vol.313 , Issue.2 , pp. 387-400
    • Koch, M.1    Pancera, M.2    Kwong, P.D.3
  • 75
    • 52449127095 scopus 로고    scopus 로고
    • Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates
    • Jun;
    • Huang Z, Chou A, Tanguay J, et al. Levels of N-linked glycosylation on the V1 loop of HIV-1 Env proteins and their relationship to the antigenicity of Env from primary viral isolates. Curr HIV Res 2008 Jun; 6 (4): 296-305
    • (2008) Curr HIV Res , vol.6 , Issue.4 , pp. 296-305
    • Huang, Z.1    Chou, A.2    Tanguay, J.3
  • 76
    • 0038414622 scopus 로고    scopus 로고
    • Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design
    • May;
    • Pantophlet R, Wilson IA, Burton DR. Hyperglycosylated mutants of human immunodeficiency virus (HIV) type 1 monomeric gp120 as novel antigens for HIV vaccine design. J Virol 2003 May; 77 (10): 5889-901
    • (2003) J Virol , vol.77 , Issue.10 , pp. 5889-5901
    • Pantophlet, R.1    Wilson, I.A.2    Burton, D.R.3
  • 77
    • 22544471847 scopus 로고    scopus 로고
    • Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: Characterization and ligand binding analysis
    • Aug;
    • Pancera M, Lebowitz J, Schon A, et al. Soluble mimetics of human immunodeficiency virus type 1 viral spikes produced by replacement of the native trimerization domain with a heterologous trimerization motif: characterization and ligand binding analysis. J Virol 2005 Aug; 79 (15): 9954-69
    • (2005) J Virol , vol.79 , Issue.15 , pp. 9954-9969
    • Pancera, M.1    Lebowitz, J.2    Schon, A.3
  • 78
    • 0033985999 scopus 로고    scopus 로고
    • A Recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure
    • Binley JM, Sanders RW, Clas B, et al. A Recombinant human immunodeficiency virus type 1 envelope glycoprotein complex stabilized by an intermolecular disulfide bond between the gp120 and gp41 subunits is an antigenic mimic of the trimeric virion-associated structure. J Virol 2000; 74 (2): 627-43
    • (2000) J Virol , vol.74 , Issue.2 , pp. 627-643
    • Binley, J.M.1    Sanders, R.W.2    Clas, B.3
  • 79
    • 0036333661 scopus 로고    scopus 로고
    • Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1
    • Sep;
    • Sanders RW, Vesanen M, Schuelke N, et al. Stabilization of the soluble, cleaved, trimeric form of the envelope glycoprotein complex of human immunodeficiency virus type 1. J Virol 2002 Sep; 76 (17): 8875-89
    • (2002) J Virol , vol.76 , Issue.17 , pp. 8875-8889
    • Sanders, R.W.1    Vesanen, M.2    Schuelke, N.3
  • 80
    • 33947590277 scopus 로고    scopus 로고
    • A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120
    • Beddows S, Franti M, Dey AK,et al. A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120. Virology 2007; 360: 329-40
    • (2007) Virology , vol.360 , pp. 329-340
    • Beddows, S.1    Franti, M.2    Dey, A.K.3
  • 81
    • 54849437925 scopus 로고    scopus 로고
    • Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site
    • Burioni R, Mancini N, De Marco D, et al. Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies mimicking the CD4-binding site. PLoS ONE 2008; 3 (10): e3423
    • (2008) PLoS ONE , vol.3 , Issue.10
    • Burioni, R.1    Mancini, N.2    De Marco, D.3
  • 82
    • 33845439080 scopus 로고    scopus 로고
    • Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector
    • Dec 15;
    • Catanzaro AT, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis 2006 Dec 15; 194 (12): 1638-49
    • (2006) J Infect Dis , vol.194 , Issue.12 , pp. 1638-1649
    • Catanzaro, A.T.1    Koup, R.A.2    Roederer, M.3
  • 83
    • 33847121696 scopus 로고    scopus 로고
    • Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: Negative results fail to trigger a phase 3 correlates trial
    • Feb 1;
    • Russell ND, Graham BS, Keefer MC, et al. Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. J Acquir Immune Defic Syndr 2007 Feb 1; 44 (2): 203-12
    • (2007) J Acquir Immune Defic Syndr , vol.44 , Issue.2 , pp. 203-212
    • Russell, N.D.1    Graham, B.S.2    Keefer, M.C.3
  • 84
    • 34247201441 scopus 로고    scopus 로고
    • Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine
    • May 16;
    • Catanzaro AT, Roederer M, Koup RA, et al. Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine. Vaccine 2007 May 16; 25 (20): 4085-92
    • (2007) Vaccine , vol.25 , Issue.20 , pp. 4085-4092
    • Catanzaro, A.T.1    Roederer, M.2    Koup, R.A.3
  • 85
    • 33845412550 scopus 로고    scopus 로고
    • Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine
    • Dec 15;
    • Graham BS, Koup RA, Roederer M, et al. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006 Dec 15; 194 (12): 1650-60
    • (2006) J Infect Dis , vol.194 , Issue.12 , pp. 1650-1660
    • Graham, B.S.1    Koup, R.A.2    Roederer, M.3
  • 86
    • 33745961311 scopus 로고    scopus 로고
    • Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults
    • Jul;
    • Mulligan MJ, Russell ND, Celum C, et al. Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. AIDS Res Hum Retroviruses 2006 Jul; 22 (7): 678-83
    • (2006) AIDS Res Hum Retroviruses , vol.22 , Issue.7 , pp. 678-683
    • Mulligan, M.J.1    Russell, N.D.2    Celum, C.3
  • 87
    • 19944425960 scopus 로고    scopus 로고
    • Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins
    • Jan;
    • Mascola JR, Sambor A, Beaudry K, et al. Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol 2005 Jan; 79 (2): 771-9
    • (2005) J Virol , vol.79 , Issue.2 , pp. 771-779
    • Mascola, J.R.1    Sambor, A.2    Beaudry, K.3
  • 88
    • 39149109930 scopus 로고    scopus 로고
    • Cross-subtype antibody and cellular immune responses induced byapolyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
    • Wang S, Kennedy JS, West K, et al. Cross-subtype antibody and cellular immune responses induced byapolyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. Vaccine 2008; 26: 3947-57
    • (2008) Vaccine , vol.26 , pp. 3947-3957
    • Wang, S.1    Kennedy, J.S.2    West, K.3
  • 89
    • 0036500532 scopus 로고    scopus 로고
    • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A
    • Mar 1;
    • Gupta K, Hudgens M, Corey L, et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 2002 Mar 1; 29 (3): 254-61
    • (2002) J Acquir Immune Defic Syndr , vol.29 , Issue.3 , pp. 254-261
    • Gupta, K.1    Hudgens, M.2    Corey, L.3
  • 90
    • 34848908400 scopus 로고    scopus 로고
    • A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost
    • Sep 1;
    • Thongcharoen P, Suriyanon V, Paris RM, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007 Sep 1; 46 (1): 48-55
    • (2007) J Acquir Immune Defic Syndr , vol.46 , Issue.1 , pp. 48-55
    • Thongcharoen, P.1    Suriyanon, V.2    Paris, R.M.3
  • 91
    • 0033496071 scopus 로고    scopus 로고
    • A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers
    • Aug;
    • Evans TG, Keefer MC, Weinhold KJ, et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 1999 Aug; 180 (2): 290-8
    • (1999) J Infect Dis , vol.180 , Issue.2 , pp. 290-298
    • Evans, T.G.1    Keefer, M.C.2    Weinhold, K.J.3
  • 92
    • 0035341521 scopus 로고    scopus 로고
    • Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: A phase 2 study in higher- and lower-risk volunteers
    • May 1;
    • Belshe RB, Stevens C, Gorse GJ, et al. Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. J Infect Dis 2001 May 1; 183 (9): 1343-52
    • (2001) J Infect Dis , vol.183 , Issue.9 , pp. 1343-1352
    • Belshe, R.B.1    Stevens, C.2    Gorse, G.J.3
  • 93
    • 0036096976 scopus 로고    scopus 로고
    • Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization
    • Jun;
    • Chakrabarti BK, Kong WP, Wu BY, et al. Modifications of the human immunodeficiency virus envelope glycoprotein enhance immunogenicity for genetic immunization. J Virol 2002 Jun; 76 (11): 5357-68
    • (2002) J Virol , vol.76 , Issue.11 , pp. 5357-5368
    • Chakrabarti, B.K.1    Kong, W.P.2    Wu, B.Y.3
  • 94
    • 13944277994 scopus 로고    scopus 로고
    • Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys
    • Mar;
    • Seaman MS, Xu L, Beaudry K, et al. Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005 Mar; 79 (5): 2956-63
    • (2005) J Virol , vol.79 , Issue.5 , pp. 2956-2963
    • Seaman, M.S.1    Xu, L.2    Beaudry, K.3
  • 95
    • 34548695901 scopus 로고    scopus 로고
    • Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multiclade HIV-1 envelope immunogens
    • Seaman MS, Leblanc DF, Grandpre LE, et al. Standardized assessment of NAb responses elicited in rhesus monkeys immunized with single- or multiclade HIV-1 envelope immunogens. Virology 2007; 367: 175-86
    • (2007) Virology , vol.367 , pp. 175-186
    • Seaman, M.S.1    Leblanc, D.F.2    Grandpre, L.E.3
  • 96
    • 0027284896 scopus 로고
    • Gene inoculation generates immune responses against human immunodeficiency virus type 1
    • May 1;
    • Wang B, Ugen KE, Srikantan V, et al. Gene inoculation generates immune responses against human immunodeficiency virus type 1. Proc Natl Acad Sci U S A 1993 May 1; 90 (9): 4156-60
    • (1993) Proc Natl Acad Sci U S A , vol.90 , Issue.9 , pp. 4156-4160
    • Wang, B.1    Ugen, K.E.2    Srikantan, V.3
  • 97
    • 0029037299 scopus 로고
    • Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice
    • Lu S, Santoro JC, Fuller DH, et al. Use of DNAs expressing HIV-1 Env and noninfectious HIV-1 particles to raise antibody responses in mice. Virology 1995; 209 (1):147-54
    • (1995) Virology , vol.209 , Issue.1 , pp. 147-154
    • Lu, S.1    Santoro, J.C.2    Fuller, D.H.3
  • 98
    • 0030155046 scopus 로고    scopus 로고
    • In vivo protective anti-HIV immune responses in non-human primates through DNA immunization
    • Jun;
    • Boyer JD, Wang B, Ugen KE, et al. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization. J Med Primatol 1996 Jun; 25 (3): 242-50
    • (1996) J Med Primatol , vol.25 , Issue.3 , pp. 242-250
    • Boyer, J.D.1    Wang, B.2    Ugen, K.E.3
  • 99
    • 0034703836 scopus 로고    scopus 로고
    • Induction of antigen-specific CD8+ T cells, T helper cells, and protective levelsofantibodyinhumans by particle-mediated administration of a hepatitis B virus DNA vaccine
    • Nov 22;
    • Roy MJ, Wu MS, Barr LJ, et al. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levelsofantibodyinhumans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000 Nov 22; 19 (7-8): 764-78
    • (2000) Vaccine , vol.19 , Issue.7-8 , pp. 764-778
    • Roy, M.J.1    Wu, M.S.2    Barr, L.J.3
  • 100
    • 0032538597 scopus 로고    scopus 로고
    • Induction of antigen-specific cytotoxic T lymphocytes in humansby a malaria DNA vaccine
    • Wang R, Doolan DL, Le TP, et al. Induction of antigen-specific cytotoxic T lymphocytes in humansby a malaria DNA vaccine. Science 1998; 282 (5388): 476-80
    • (1998) Science , vol.282 , Issue.5388 , pp. 476-480
    • Wang, R.1    Doolan2    DL, L.T.3
  • 101
    • 17444435761 scopus 로고    scopus 로고
    • Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
    • May 2;
    • Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998 May 2; 351 (9112): 1320-5
    • (1998) Lancet , vol.351 , Issue.9112 , pp. 1320-1325
    • Calarota, S.1    Bratt, G.2    Nordlund, S.3
  • 102
    • 0005457558 scopus 로고    scopus 로고
    • First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
    • Jul;
    • MacGregor RR, Boyer JD, Ugen KE,et al. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: safety and host response. J Infect Dis 1998 Jul; 178 (1): 92-100
    • (1998) J Infect Dis , vol.178 , Issue.1 , pp. 92-100
    • MacGregor, R.R.1    Boyer, J.D.2    Ugen, K.E.3
  • 103
    • 0032210747 scopus 로고    scopus 로고
    • DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans
    • Ugen KE, Nyland SB, Boyer JD, et al. DNA vaccination with HIV-1 expressing constructs elicits immune responses in humans. Vaccine 1998; 16 (19): 1818-21
    • (1998) Vaccine , vol.16 , Issue.19 , pp. 1818-1821
    • Ugen, K.E.1    Nyland, S.B.2    Boyer, J.D.3
  • 104
    • 0030917744 scopus 로고    scopus 로고
    • Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting
    • Apr 14;
    • Richmond JF, Mustafa F, Lu S, et al. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting. Virology 1997 Apr 14; 230 (2): 265-74
    • (1997) Virology , vol.230 , Issue.2 , pp. 265-274
    • Richmond, J.F.1    Mustafa, F.2    Lu, S.3
  • 105
    • 0031550774 scopus 로고    scopus 로고
    • HIV-1 Env glycoproteins from two series of primary isolates: Replication phenotype and immunogenicity
    • Mar 3;
    • Mustafa F, Richmond JF, Fernandez-Larsson R, et al. HIV-1 Env glycoproteins from two series of primary isolates: replication phenotype and immunogenicity. Virology 1997 Mar 3; 229 (1): 269-78
    • (1997) Virology , vol.229 , Issue.1 , pp. 269-278
    • Mustafa, F.1    Richmond, J.F.2    Fernandez-Larsson, R.3
  • 106
    • 13744254539 scopus 로고    scopus 로고
    • Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system
    • Feb;
    • Wang S, Chou TH, Sakhatskyy PV, et al. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol 2005 Feb; 79 (3): 1906-10
    • (2005) J Virol , vol.79 , Issue.3 , pp. 1906-1910
    • Wang, S.1    Chou, T.H.2    Sakhatskyy, P.V.3
  • 107
    • 0032920019 scopus 로고    scopus 로고
    • Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations
    • Robinson HL, Montefiori DC, Johnson RP, et al. Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. Nat Med 1999; 5 (5): 526-34
    • (1999) Nat Med , vol.5 , Issue.5 , pp. 526-534
    • Robinson, H.L.1    Montefiori, D.C.2    Johnson, R.P.3
  • 108
    • 23644440075 scopus 로고    scopus 로고
    • Electroporation for targeted gene transfer
    • Mar;
    • Heller LC, Ugen K, Heller R. Electroporation for targeted gene transfer. Expert Opin Drug Deliv 2005 Mar; 2 (2): 255-68
    • (2005) Expert Opin Drug Deliv , vol.2 , Issue.2 , pp. 255-268
    • Heller, L.C.1    Ugen, K.2    Heller, R.3
  • 109
    • 41549123253 scopus 로고    scopus 로고
    • The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods
    • Apr 16;
    • Wang S, Zhang C, Zhang L, et al. The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine 2008 Apr 16; 26 (17): 2100-10
    • (2008) Vaccine , vol.26 , Issue.17 , pp. 2100-2110
    • Wang, S.1    Zhang, C.2    Zhang, L.3
  • 110
    • 0035850961 scopus 로고    scopus 로고
    • Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device
    • Oct 12;
    • Aguiar JC, Hedstrom RC, Rogers WO, et al. Enhancement of the immune response in rabbits to a malaria DNA vaccine by immunization with a needle-free jet device. Vaccine 2001 Oct 12; 20 (1-2): 275-80
    • (2001) Vaccine , vol.20 , Issue.1-2 , pp. 275-280
    • Aguiar, J.C.1    Hedstrom, R.C.2    Rogers, W.O.3
  • 111
    • 0033605223 scopus 로고    scopus 로고
    • Intradermal DNA immunization by using jet-injectors in mice and monkeys
    • Feb 26;
    • Haensler J, Verdelet C, Sanchez V, et al. Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999 Feb 26; 17 (7-8): 628-38
    • (1999) Vaccine , vol.17 , Issue.7-8 , pp. 628-638
    • Haensler, J.1    Verdelet, C.2    Sanchez, V.3
  • 112
    • 10744223658 scopus 로고    scopus 로고
    • Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe
    • Sep 8;
    • Trimble C, Lin CT, Hung CF, et al. Comparison of the CD8+ T cell responses and antitumor effects generated by DNA vaccine administered through gene gun, biojector, and syringe. Vaccine 2003 Sep 8; 21 (25-26): 4036-42
    • (2003) Vaccine , vol.21 , Issue.25-26 , pp. 4036-4042
    • Trimble, C.1    Lin, C.T.2    Hung, C.F.3
  • 113
    • 1542358759 scopus 로고    scopus 로고
    • Microneedles for transdermal drug delivery
    • Mar 27;
    • Prausnitz MR. Microneedles for transdermal drug delivery. Adv Drug Deliv Rev 2004 Mar 27; 56 (5): 581-7
    • (2004) Adv Drug Deliv Rev , vol.56 , Issue.5 , pp. 581-587
    • Prausnitz, M.R.1
  • 114
    • 0034755765 scopus 로고    scopus 로고
    • Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein
    • Nov;
    • Deml L, Bojak A, Steck S, et al. Multiple effects of codon usage optimization on expression and immunogenicity of DNA candidate vaccines encoding the human immunodeficiency virus type 1 Gag protein. J Virol 2001 Nov; 75 (22): 10991-1001
    • (2001) J Virol , vol.75 , Issue.22 , pp. 10991-11001
    • Deml, L.1    Bojak, A.2    Steck, S.3
  • 115
    • 33646840487 scopus 로고    scopus 로고
    • Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine
    • May 22;
    • Wang S, Farfan-Arribas DJ, Shen S, et al. Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. Vaccine 2006 May 22; 24 (21): 4531-40
    • (2006) Vaccine , vol.24 , Issue.21 , pp. 4531-4540
    • Wang, S.1    Farfan-Arribas, D.J.2    Shen, S.3
  • 116
    • 0034056240 scopus 로고    scopus 로고
    • Increased expression and im-munogenicity of sequence-modified human immunodeficiency virus type 1 gag gene
    • zur Megede JZ, Chen MC, Doe B, et al. Increased expression and im-munogenicity of sequence-modified human immunodeficiency virus type 1 gag gene. J Virol 2000; 74 (6): 2628-35
    • (2000) J Virol , vol.74 , Issue.6 , pp. 2628-2635
    • zur Megede, J.Z.1    Chen, M.C.2    Doe, B.3
  • 117
    • 33751071573 scopus 로고    scopus 로고
    • Combination DNA plus protein HIV vaccines
    • Nov;
    • Lu S. Combination DNA plus protein HIV vaccines. Springer Semin Im-munopathol 2006 Nov; 28 (3): 255-65
    • (2006) Springer Semin Im-munopathol , vol.28 , Issue.3 , pp. 255-265
    • Lu, S.1
  • 118
    • 0031657986 scopus 로고    scopus 로고
    • Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting
    • Richmond JF, Lu S, Santoro JC, et al. Studies of the neutralizing activity and avidity of anti-human immunodeficiency virus type 1 Env antibody elicited by DNA priming and protein boosting. J Virol 1998; 72 (11): 9092-100
    • (1998) J Virol , vol.72 , Issue.11 , pp. 9092-9100
    • Richmond, J.F.1    Lu, S.2    Santoro, J.C.3
  • 119
    • 0030872511 scopus 로고    scopus 로고
    • Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit
    • Jun;
    • Barnett SW, Rajasekar S, Legg H, et al. Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit. Vaccine 1997 Jun; 15 (8): 869-73
    • (1997) Vaccine , vol.15 , Issue.8 , pp. 869-873
    • Barnett, S.W.1    Rajasekar, S.2    Legg, H.3
  • 120
    • 12644271200 scopus 로고    scopus 로고
    • Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination
    • Aug 19;
    • Letvin NL, Montefiori DC, Yasutomi Y, et al. Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA plus protein vaccination. Proc Natl Acad Sci U S A 1997 Aug 19; 94 (17): 9378-83
    • (1997) Proc Natl Acad Sci U S A , vol.94 , Issue.17 , pp. 9378-9383
    • Letvin, N.L.1    Montefiori, D.C.2    Yasutomi, Y.3
  • 121
    • 19944393561 scopus 로고    scopus 로고
    • Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1
    • Jun;
    • Wang S, Arthos J, Lawrence JM, et al. Enhanced immunogenicity of gp120 protein when combined with recombinant DNA priming to generate antibodies that neutralize the JR-FL primary isolate of human immunodeficiency virus type 1. J Virol 2005 Jun; 79 (12): 7933-7
    • (2005) J Virol , vol.79 , Issue.12 , pp. 7933-7937
    • Wang, S.1    Arthos, J.2    Lawrence, J.M.3
  • 122
    • 33746651142 scopus 로고    scopus 로고
    • Wang S,Pal R, Mascola JR, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006 Jun 20; 350 (1): 34-47
    • Wang S,Pal R, Mascola JR, et al. Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. Virology 2006 Jun 20; 350 (1): 34-47
  • 123
    • 33745496632 scopus 로고    scopus 로고
    • Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype
    • May 10;
    • Pal R, Wang S, Kalyanaraman VS, et al. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype. Virology 2006 May 10; 348 (2): 341-53
    • (2006) Virology , vol.348 , Issue.2 , pp. 341-353
    • Pal, R.1    Wang, S.2    Kalyanaraman, V.S.3
  • 124
    • 0036099015 scopus 로고    scopus 로고
    • DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus
    • Feb;
    • Rasmussen RA, Hofmann-Lehman R, Montefiori DC, et al. DNA prime/protein boost vaccine strategy in neonatal macaques against simian human immunodeficiency virus. J Med Primatol 2002 Feb; 31 (1): 40-60
    • (2002) J Med Primatol , vol.31 , Issue.1 , pp. 40-60
    • Rasmussen, R.A.1    Hofmann-Lehman, R.2    Montefiori, D.C.3
  • 125
    • 33845207796 scopus 로고    scopus 로고
    • Durable HIV-1 antibody and T-cell responses elicitedby an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
    • Goepfert PA, Tomaras GD, Horton H, et al. Durable HIV-1 antibody and T-cell responses elicitedby an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. Vaccine 2007; 25: 510-8
    • (2007) Vaccine , vol.25 , pp. 510-518
    • Goepfert, P.A.1    Tomaras, G.D.2    Horton, H.3
  • 126
    • 48449105674 scopus 로고    scopus 로고
    • The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers
    • Aug 18;
    • Kennedy JS, Co M, Green S, et al. The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers. Vaccine 2008 Aug 18; 26 (35): 4420-4
    • (2008) Vaccine , vol.26 , Issue.35 , pp. 4420-4424
    • Kennedy, J.S.1    Co, M.2    Green, S.3
  • 127
    • 47749129289 scopus 로고    scopus 로고
    • Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination
    • Aug;
    • Vaine M, Wang S, Crooks ET, et al. Improved induction of antibodies against key neutralizing epitopes by human immunodeficiency virus type 1 gp120 DNA prime-protein boost vaccination compared to gp120 protein-only vaccination. J Virol 2008 Aug; 82 (15): 7369-78
    • (2008) J Virol , vol.82 , Issue.15 , pp. 7369-7378
    • Vaine, M.1    Wang, S.2    Crooks, E.T.3
  • 128
    • 34948854718 scopus 로고    scopus 로고
    • Broad HIV-1 neutralization mediated by CD4-binding site antibodies
    • Sep;
    • Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007 Sep; 13 (9): 1032-4
    • (2007) Nat Med , vol.13 , Issue.9 , pp. 1032-1034
    • Li, Y.1    Migueles, S.A.2    Welcher, B.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.